ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2025

The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome.

Jun Ho Jang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.